Sienna Biopharmaceuticals, Inc.

It's ugly out there for biopharmaceutical stocks in the US with the Nasdaq Biotechnology Index (NBI) down 2.1% over the past month, which has had a chilling effect on initial public offerings for the

Pfizer Inc. already is a leader in Janus kinase (JAK) inhibition with its blockbuster Xeljanz (tofacitinib) in various indications, but the company's first set of Phase III data for its second JAK-ta

The US market for initial public offerings by biopharmaceutical companies didn't get into full gear until February, but seven companies rushed to push their IPOs through the open window this month. Ne

Regulus Therapeutics Inc. , which has been struggling for years, said on July 6 that it is cutting its head count by 60%, halting enrollment in its two clinical programs, and reprioritizing its precli